A Reflux Nobody's Antibiotic Can Fix
A transplant recipient's fourth febrile urinary tract infection this year traces back to reflux at the ureteral reimplant site, not to any organism — and the debate is no longer about which drug, but how many more courses of one are worth trying before the answer is a second operation.
D.K., a 34-year-old woman who manages a community food bank, received a living-donor kidney from her father four years ago after a childhood case of posterior urethral valves left her with progressive chronic kidney disease into adulthood — a detail from her own history that nobody thought was still relevant to her transplant course until this year forced the team to look at it again. Her graft function has otherwise been excellent, creatinine steady at 1.0 for the past three years, and she has no diabetes, no other chronic illness, and describes herself as someone who “hasn't been sick a day” since the surgery, apart from this, a self-assessment her chart mostly backs up: one clinic visit for a sinus infection in four years, otherwise unremarkable.
This year alone she has had four febrile urinary tract infections in the graft, each treated with a different culture-directed antibiotic and each resolving completely before the next one started — a pattern that is itself a finding, not just bad luck repeating. The organism keeps changing (E. coli twice, then Klebsiella, then Enterococcus), which argues against a single resistant colonizer persisting between courses and toward a mechanical explanation instead, something reintroducing bacteria regardless of which one gets cleared each time. A voiding cystourethrogram ordered after the third episode showed grade 3 reflux at the ureteroneocystostomy site, refluxing contrast well up toward the renal pelvis on a full bladder — the same native-kidney posterior urethral valve history now appearing, in a different form, in the new one. Dinckan and colleagues followed sixty transplant recipients with this same finding through surgical correction and found their febrile UTI rate fall from a median of four episodes a year beforehand to one afterward, a statistically significant drop; D.K.'s own count this year, before any intervention at all, already matches their patients' pre-operative median exactly.
After the fourth episode, deciding what kind of fix this needs
Try fosfomycin prophylaxis first. It's not a strong intervention, but it's a real one, and it doesn't ask an immunosuppressed patient to heal a new incision on top of everything her regimen already works against.
I'm not arguing this reflux is imaginary or that surgery is never warranted here — I'm arguing we haven't actually tried the cheapest, lowest-risk option yet, and four episodes in one year, while genuinely bad, is still a number a prophylactic regimen hasn't had a chance to move.
Four organisms in one year is the finding, not a coincidence to explain away. Dinckan's series followed sixty patients with graded reflux and recurrent febrile UTI through surgical correction and measured a real drop — median four episodes a year before, one after, statistically significant.
Fosfomycin prophylaxis doesn't touch the actual mechanism here — urine is still refluxing up a dilated ureter every time she voids with a full bladder. It might suppress the next organism for a few months, the way the last four courses suppressed the last four, and then we're back at this same table with a fifth.
There's a step between antibiotics and open reimplantation. Endoscopic injection of a bulking agent at the reflux site — cystoscopic, no incision, done as an outpatient procedure — has at least one published case with full resolution of reflux and no further pyelonephritis across more than four years of follow-up.
It isn't as extensively studied in transplant recipients as open reimplantation is, and it may not hold up as durably in a grade 3 reflux this significant. But it's a real option worth offering before asking her to accept the recovery and adhesion risk of a second open operation on a graft that, apart from this, is working exactly the way everyone wants it to.
Agreed: fosfomycin prophylaxis starts today, with a formal urology referral for endoscopic bulking-agent injection scheduled within the month rather than left open-ended — a deliberate compromise between the nephrologist's caution about a second surgery and the urologist's read that antibiotics alone are chasing a mechanism they can't fix.
Genuinely unresolved: how many more febrile episodes, if the bulking injection doesn't hold, would settle the argument in favor of open reimplantation outright. Nobody at the table named a number, and the case was left exactly where the pivot itself lives — not with a wrong answer corrected, but with a real threshold nobody has agreed on yet.